The chemotherapy of chagas' disease: an overview.
The review presents: a) a brief description of the disease; b) a summary of the most important metabolic targets so far identified in Trypanosome cruzi (T. cruzi) along with corresponding inhibitor compounds; c) the current state of knowledge on the trypanothione reductase system of trypanosomatids with reference to oxidative stress defenses; d) detailed discussions on T. cruzi trypanothione reductase inhibitors such as nitrofuranes, naphthoquinones and phenothiazines. As yet, the chemotherapy of Chagas' disease remains an unsolved problem. Further search for new drugs must continue by means of nucleating existing chemotherapy efforts.
Paulino
M
M
Departamento de Químico-Física y Matemáticas, Facultad de Química, Universidad de la Republica. Gral. Flores, 2124, 11800 Montevideo, Uruguay. margot@fq.edu.uy
Iribarne
F
F
Dubin
M
M
Aguilera-Morales
S
S
Tapia
O
O
Stoppani
A O M
AO
D000818:Animals; D014355:Chagas Disease / Q000188:drug therapy*; D006801:Humans; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014344:Trypanocidal Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D014349:Trypanosoma cruzi / Q000187:drug effects* / Q000201:enzymology; D014351:Trypanosomatina / Q000187:drug effects* / Q000201:enzymology
D014344:Trypanocidal Agents; D009247:NADH, NADPH Oxidoreductases; C049608:trypanothione reductase